Hassle-free dosing eliminates the need for pilling.
INDICATIONS
SEMINTRA® (telmisartan oral solution) is indicated for the control of systemic hypertension in cats.
CLINICAL BENEFITS
SEMINTRA® (telmisartan oral solution) is the first and only FDA-approved treatment for feline hypertension in an easy-to-give liquid formulation.1,2 SEMINTRA oral solution safely and quickly lowers blood pressure to a healthy level within 14 days.3
Easy-to-Use Syringe
• Flexible delivery of dose straight into the mouth or on top of food4
• Calibrated for accurate dosing
Safe for Long-Term Administration
• Once-daily dosing after 14 days
• Safety demonstrated in multiple studies1-3,5
Convenient Liquid Formulation
• As demonstrated in a survey: 91.2% of cat owners prefer a liquid formulation4
Best-Positioned Anti-Hypertensive to Deal With an Activated Renin-Angiotensin-Aldosterone-System (RAAS)
Telmisartan, the active substance in SEMINTRA oral solution, is an angiotensin receptor blocker (ARB), a class of medication that modulates the RAAS by selectively blocking the effects of the angiotensin II type 1 (AT1) receptor that is primarily responsible for vasoconstriction. This targeted mode of action of SEMINTRA oral solution ensures that beneficial effects mediated by the angiotensin II type 2 (AT2), and other receptors, are spared, unlike angiotensin-converting enzyme inhibitors (ACE-1) whose RAAS blocking action produces poor anti-hypertensive effect.6 And, although also recognized as anti-hypertensive, calcium channel blockers like amlodipine may potentially activate the RAAS.7
DOSAGE & ADMINISTRATION
Flexible Dosing to Safely Lower and Maintain Blood Pressure in Cats
The initial dose of SEMINTRA® (telmisartan oral solution) is 1.5 mg/kg (0.68 mg/lb) orally twice daily for 14 days, followed by 2 mg/kg (0.91 mg/lb) orally once daily. The dose may be reduced by 0.5 mg/kg (0.23 mg/lb) increments to a minimum of 0.5mg/kg (0.23 mg/lb) orally once daily to manage SEMINTRA-induced hypotension.
SEMINTRA oral solution can be administered directly in the mouth, or next to or on top of a small amount of food. Do not mix into food.
SEMINTRA oral solution should be administered using the dosing syringe provided in the package. The dosing syringe fits onto the bottle and has 0.1 mL incremental marks. The dose should be rounded to the nearest 0.1 mL. If the cat vomits within 30 minutes of dosing, the cat may be re-dosed.
SAFETY
Always provide the Client Information Sheet with each prescription and review it with the cat owner. Advise cat owners that adverse reactions can occur with use of SEMINTRA® (telmisartan oral solution). The most common adverse reactions reported during the field studies included vomiting, diarrhea, lethargy, weight loss, anemia, and dehydration.
Contraindications: Do not use in cats with a hypersensitivity to telmisartan.
Human Warnings: Not for human use. Keep out of reach of children.
SEMINTRA oral solution is an angiotensin II antagonist/angiotensin receptor blocker (ARB). Pregnant women should avoid contact with SEMINTRA oral solution because substances that act on the renin-angiotensin-aldosterone system (RAAS) such as angiotensin receptor blockers (ARBs) can cause fetal and neonatal morbidity and death during pregnancy in humans.
Precautions: SEMINTRA oral solution has not been evaluated in cats with systolic blood pressure >200 mm Hg.
SEMINTRA oral solution can cause mild anemia or non-regenerative anemia. Cats should be monitored for anemia when initiating treatment with SEMINTRA oral solution.
SEMINTRA oral solution may cause inappetence and weight loss in some cats. Cats should be monitored for weight loss when initiating treatment with SEMINTRA oral solution. Use with caution in cats with a history of vomiting, inappetence or weight loss.
The safe use of SEMINTRA oral solution in cats with hepatic disease has not been evaluated. SEMINTRA oral solution is metabolized by the liver.
The safe use of SEMINTRA oral solution has not been evaluated in cats less than 9 months of age.
The safe use of SEMINTRA oral solution has not been evaluated in cats that are pregnant, lactating, or intended for breeding. See Human Warnings.
The safe use with other anti-hypertensive medications has not been evaluated.
For more information, please see full prescribing information.
Highly Accepted By Cats
The liquid formulation of SEMINTRA oral solution eliminates the inconvenience and potential challenge of pilling a cat. Long-term daily pilling can be damaging to the human-animal bond. Nine out of ten pet owners prefer a liquid formulation.4
The SEMINTRA oral solution syringe is a key differentiator versus a scored pill. SEMINTRA oral solution can be delivered straight into the mouth or on top of food.4 Because amlodipine is a scored pill with unequal amounts of medicine in each half, it is impossible to know how much medicine the cat is digesting. There are potential risks of overdosing and potential clinical inadequacy. Consistent daily dosing is more likely with SEMINTRA oral solution.
SEMINTRA is safe for chronic use when used per label. It has been proven to safely lower blood pressure in 14 days.3 Multiple studies include safety data of up to 6 months.3-5
Downloadable Content
Resource Developed With the American Animal Hospital Association (AAHA)
Resource Developed With Clinician’s Brief
White Papers
Important Links
References
- Coleman AE, Brown SA, Traas AM, et al. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019;33(2):478-488.
- Glaus AM, Elliott J, Albrecht B, et al. Efficacy of telmisartan in hypertensive cats: results of a large European clinical trial. J Vet Intern Med. 2019;32:577.
- Coleman AE, Brown SA, Stark M. Evaluation of orally administered telmisartan for the reduction of indirect systolic arterial blood pressure in awake, clinically normal cats. J Feline Med Surg. 2019:21(2):109-114.
- Zimmering T. Ease of use of SEMINTRA and its effects on quality of life–update on cat owner feedback (“EASY Programme”). Poster presented at: 21st Federation of European Companion Animal Veterinary Associations (FECAVA); October 15-17, 2015; Barcelona, Spain.
- SEMINTRA® (telmisartan oral solution) [Freedom of Information Summary; NADA 141-501]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.: 2018.
- Taylor SS. Sparkes AH, Briscoe K, et al. ISFM Consensus Guidelines on the diagnosis and management of hypertension in cats. J Feline Med Surg. 2017,19(3):288-303.
- Jepson R. Syme H, Elliott J. Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate. J Vet Intern Med. 2014;28:144-153.
- Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. JVIM. 2018;32(6):1803-1822.
Trademarks
SEMINTRA® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trademarks are the property of their respective owner. ©2023 Boehringer Ingelheim Animal Health. USA Inc., Duluth, GA. All rights reserved.
US-PET-0564-2020-V2